Arbutus Biopharma's EBIT per Share for the
three
months ended in Mar. 2026 was $0.87.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.82.
During the past 3 years, the average EBIT per Share Growth Rate was 30.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 24.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 18.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Arbutus Biopharma's EBIT per Share or its related term are showing as below:
ABUS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -93.9 Med: 5.6 Max: 66.2
Current: 30.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Arbutus Biopharma was 66.20% per year. The lowest was -93.90% per year. And the median was 5.60% per year.
ABUS's 3-Year EBIT Growth Rate is ranked better than 68.84% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs ABUS: 30.40
Arbutus Biopharma (NAS:ABUS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Arbutus Biopharma EBIT per Share Related Terms
Arbutus Biopharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a EBIT per Share of $0.82 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arbutus Biopharma and its competitors. According to the industry distribution chart, Arbutus Biopharma ranks #368 out of 1181 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Arbutus Biopharma's EBIT per Share too high?
Arbutus Biopharma's current EBIT per Share is $0.82. The Biotechnology industry median EBIT per Share is 15.50. Arbutus Biopharma's value of $0.82 is 94.7% below this industry median. Based on the distribution chart, Arbutus Biopharma ranks #368 out of 1181 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's EBIT per Share compare to EVMN and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #368 out of 1181 companies for EBIT per Share. This puts Arbutus Biopharma in the upper half of its industry. The industry median EBIT per Share is 15.50. Arbutus Biopharma's value of $0.82 is 94.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current EBIT per Share of $0.82 is 94.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current EBIT per Share is $0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.39, compared to a current price of $4.68 — trading 90.9% below its estimated fair value. The current EBIT per Share is $0.82 and 94.7% below the Biotechnology industry median of 15.50. Arbutus Biopharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current EBIT per Share is $0.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.68 is trading 90.9% below its estimated GF Value™ of $51.39.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
EBIT per Share: $0.82
GF Value™: $51.39 vs. price of $4.68 (90.9% below fair value)
Industry Position: 94.7% below the Biotechnology median (#368 of 1181)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score
Get the complete analysis for ABUS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
